• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PureTech Health plc

    12/16/24 8:05:26 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTC alert in real time by email
    6-K 1 d729289d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

    For the month of December, 2024

    Commission File Number 001-39670

     

     

    PURETECH HEALTH PLC

    (Translation of registrant’s name into English)

     

     

    6 Tide Street, Suite 400

    Boston, Massachusetts 02210

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

     

     


    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

    On December 16, 2024, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) issued a press release titled “PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial.”

    The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

    Exhibits

     

    99.1

    Press Release of PureTech Health plc, dated December  16, 2024, titled “PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial.”


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

        PURETECH HEALTH PLC
    Date: December 16, 2024     By:  

    /s/ Bharatt Chowrira

          Name: Bharatt Chowrira
          Title: Chief Executive Officer
    Get the next $PRTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRTC

    DatePrice TargetRatingAnalyst
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    8/25/2021$74.00 → $76.00Outperform
    SVB Leerink
    More analyst ratings

    $PRTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

      Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) Regulatory and strategic planning underway to advance deupirfenidone into Phase 3 development PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the Company will deliver a late-breaking oral presentation at the upcoming American Thoracic Society (ATS) International Conference, taking place in San Francisco, California, from May 16-21, 2025.

      5/1/25 7:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Announces Annual Results for Year Ended December 31, 2024

      Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 20

      4/30/25 2:00:00 AM ET
      $PRTC
      $VOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • PureTech Health: Notice of Results

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

      4/23/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTC
    SEC Filings

    See more
    • SEC Form 20-F filed by PureTech Health plc

      20-F - PureTech Health plc (0001782999) (Filer)

      4/30/25 10:43:35 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PureTech Health plc

      6-K - PureTech Health plc (0001782999) (Filer)

      4/30/25 6:30:13 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by PureTech Health plc

      6-K - PureTech Health plc (0001782999) (Filer)

      4/7/25 4:15:13 PM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTC
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Appoints Peel Hunt as Joint UK Corporate Broker

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeut

      4/9/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • PureTech Appoints UBS as UK Corporate Broker

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, includ

      1/6/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners resumed coverage on PureTech Health plc with a new price target

      Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

      9/9/24 7:42:36 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on PureTech Health with a new price target

      SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously

      1/7/22 4:34:06 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on PureTech Health with a new price target

      SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously

      8/25/21 4:40:14 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PureTech Health plc

      SC 13G - PureTech Health plc (0001782999) (Subject)

      11/12/24 1:29:13 PM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PureTech Health plc

      SC 13G/A - PureTech Health plc (0001782999) (Subject)

      11/7/24 9:47:57 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by PureTech Health plc (Amendment)

      SC 13G/A - PureTech Health plc (0001782999) (Subject)

      2/12/24 4:48:30 PM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRTC
    Financials

    Live finance-specific insights

    See more
    • PureTech Health: Notice of Results

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

      4/23/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

      Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID1) and deupirfenidone 825 mg TID and successfully demonstrated dose-dependent response Decline in lung function seen with deupirfenidone 825 mg TID as a monotherapy was -21.5 mL; natural lung function decline expected in healthy adults >60 years is ~-15 to ~-25 mL2; decline in lung function with pirfenidone 801 mg TID was -51.6 mL Deupirfenidone 825 mg TID showed strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, while pirfenidone 801 mg TID had a 54.1% treatment effect versus placebo De

      12/16/24 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Health plc – Half-Year Report

      Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

      8/28/24 2:01:00 AM ET
      $AKLI
      $BMY
      $PRTC
      $VOR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)